14.38
price down icon2.38%   -0.35
after-market 시간 외 거래: 14.38
loading
전일 마감가:
$14.73
열려 있는:
$14.58
하루 거래량:
1.42M
Relative Volume:
0.88
시가총액:
$2.48B
수익:
$890.53M
순이익/손실:
$30.57M
주가수익비율:
79.89
EPS:
0.18
순현금흐름:
$80.53M
1주 성능:
-3.23%
1개월 성능:
-14.35%
6개월 성능:
-2.57%
1년 성능:
-14.51%
1일 변동 폭
Value
$14.17
$14.74
1주일 범위
Value
$14.17
$15.18
52주 변동 폭
Value
$13.40
$20.68

Acadia Pharmaceuticals Inc Stock (ACAD) Company Profile

Name
명칭
Acadia Pharmaceuticals Inc
Name
전화
858-558-2871
Name
주소
12830 EL CAMINO REAL, SAN DIEGO
Name
직원
654
Name
트위터
@acadiapharma
Name
다음 수익 날짜
2024-11-06
Name
최신 SEC 제출 서류
Name
ACAD's Discussions on Twitter

ACAD을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
ACAD
Acadia Pharmaceuticals Inc
14.38 2.48B 890.53M 30.57M 80.53M 0.18
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
477.52 127.47B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
561.49 62.43B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
595.70 37.03B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
232.75 31.06B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
229.22 26.16B 3.81B -644.79M -669.77M -6.24

Acadia Pharmaceuticals Inc Stock (ACAD) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2025-02-11 개시 Deutsche Bank Hold
2025-01-03 다운그레이드 Guggenheim Buy → Neutral
2024-10-10 재개 Raymond James Mkt Perform
2024-08-07 다운그레이드 Morgan Stanley Overweight → Equal-Weight
2024-06-27 개시 BMO Capital Markets Outperform
2024-03-12 다운그레이드 Mizuho Buy → Neutral
2024-03-12 재확인 Needham Buy
2024-01-30 개시 Robert W. Baird Outperform
2024-01-24 업그레이드 Needham Hold → Buy
2023-12-19 업그레이드 Morgan Stanley Equal-Weight → Overweight
2023-12-14 다운그레이드 Deutsche Bank Buy → Hold
2023-12-13 개시 Citigroup Buy
2023-12-12 개시 Deutsche Bank Buy
2023-11-06 업그레이드 Mizuho Neutral → Buy
2023-10-17 개시 UBS Buy
2023-10-10 업그레이드 JP Morgan Neutral → Overweight
2023-01-03 업그레이드 Guggenheim Neutral → Buy
2022-11-04 다운그레이드 Goldman Neutral → Sell
2022-11-01 개시 Loop Capital Hold
2022-08-08 다운그레이드 Citigroup Buy → Neutral
2022-08-05 다운그레이드 Citigroup Buy → Neutral
2022-06-21 다운그레이드 Jefferies Buy → Underperform
2022-06-16 업그레이드 Jefferies Hold → Buy
2022-03-16 업그레이드 Canaccord Genuity Hold → Buy
2022-02-09 업그레이드 H.C. Wainwright Neutral → Buy
2022-01-05 업그레이드 Citigroup Neutral → Buy
2021-12-21 다운그레이드 Guggenheim Buy → Neutral
2021-11-01 업그레이드 Guggenheim Neutral → Buy
2021-10-14 다운그레이드 Morgan Stanley Overweight → Equal-Weight
2021-09-23 재개 Needham Hold
2021-06-10 개시 Berenberg Hold
2021-04-07 다운그레이드 H.C. Wainwright Buy → Neutral
2021-04-06 다운그레이드 Canaccord Genuity Buy → Hold
2021-04-06 다운그레이드 Goldman Buy → Neutral
2021-04-06 다운그레이드 Jefferies Buy → Hold
2021-04-06 다운그레이드 Mizuho Buy → Neutral
2021-04-05 다운그레이드 Raymond James Outperform → Mkt Perform
2021-03-10 다운그레이드 BofA Securities Buy → Neutral
2021-03-09 다운그레이드 Citigroup Buy → Neutral
2021-03-09 다운그레이드 Guggenheim Buy → Neutral
2021-03-09 재확인 H.C. Wainwright Buy
2021-03-09 다운그레이드 Raymond James Strong Buy → Outperform
2021-03-09 다운그레이드 Stifel Buy → Hold
2020-12-16 개시 Mizuho Buy
2020-11-16 업그레이드 Raymond James Outperform → Strong Buy
2020-08-25 개시 Raymond James Outperform
2020-08-20 개시 Morgan Stanley Overweight
2020-07-07 업그레이드 Stifel Hold → Buy
2020-04-16 개시 Jefferies Buy
2020-03-31 업그레이드 Goldman Neutral → Buy
2020-03-06 개시 Citigroup Buy
2019-12-16 개시 Guggenheim Buy
2019-10-24 개시 Oppenheimer Perform
2019-10-01 개시 RBC Capital Mkts Outperform
2019-09-13 업그레이드 SVB Leerink Mkt Perform → Outperform
2019-09-10 업그레이드 Canaccord Genuity Hold → Buy
2019-07-23 재확인 Needham Buy
2018-12-10 개시 Canaccord Genuity Hold
2018-09-21 업그레이드 Piper Jaffray Neutral → Overweight
2018-08-09 재확인 Stifel Hold
2018-08-07 개시 Stifel Hold
2018-08-06 다운그레이드 Piper Jaffray Overweight → Neutral
2017-10-06 재개 Goldman Neutral
모두보기

Acadia Pharmaceuticals Inc 주식(ACAD)의 최신 뉴스

pulisher
Apr 20, 2025

Acadia Pharmaceuticals (ACAD) Price Target Lowered by BofA Before Q1 Earnings | ACAD Stock News - GuruFocus

Apr 20, 2025
pulisher
Apr 17, 2025

BofA Adjusts Price Target on ACADIA Pharmaceuticals to $18 From $19, Keeps Neutral Rating - marketscreener.com

Apr 17, 2025
pulisher
Apr 15, 2025

Schizophrenia Market to Reach New Heights in Growth by 2034, - openPR.com

Apr 15, 2025
pulisher
Apr 13, 2025

Declining Stock and Solid Fundamentals: Is The Market Wrong About ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)? - Yahoo Finance

Apr 13, 2025
pulisher
Apr 12, 2025

Lobbying Update: $20,000 of ACADIA PHARMACEUTICALS INC. lobbying was just disclosed - Quiver Quantitative

Apr 12, 2025
pulisher
Apr 11, 2025

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Li - GuruFocus

Apr 11, 2025
pulisher
Apr 11, 2025

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ACAD Stock News - GuruFocus

Apr 11, 2025
pulisher
Apr 11, 2025

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire

Apr 11, 2025
pulisher
Apr 11, 2025

Neuroscience Leader Acadia Expands Team with Major Equity Compensation Package - Stock Titan

Apr 11, 2025
pulisher
Apr 09, 2025

Acadia Pharmaceuticals principal accounting officer sells $15,234 in stock By Investing.com - Investing.com South Africa

Apr 09, 2025
pulisher
Apr 09, 2025

Acadia Pharmaceuticals principal accounting officer sells $15,234 in stock - Investing.com Australia

Apr 09, 2025
pulisher
Apr 08, 2025

Acadia Pharmaceuticals CFO sells $40,132 in stock - Investing.com India

Apr 08, 2025
pulisher
Apr 08, 2025

Acadia Pharmaceuticals CFO sells $40,132 in stock By Investing.com - Investing.com South Africa

Apr 08, 2025
pulisher
Apr 08, 2025

ACADIA Pharmaceuticals Executives Sell Shares to Cover Taxes - TradingView

Apr 08, 2025
pulisher
Apr 08, 2025

Is Weakness In ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects? - simplywall.st

Apr 08, 2025
pulisher
Mar 31, 2025

DEADLINE TOMORROW: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against ACADIA Pharmaceuticals Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm - Business Wire

Mar 31, 2025
pulisher
Mar 31, 2025

ACADIA Pharmaceuticals Earns Relative Strength Rating Upgrade - Investor's Business Daily

Mar 31, 2025
pulisher
Mar 28, 2025

Why Is Acadia (ACAD) Down 11.1% Since Last Earnings Report? - Yahoo Finance

Mar 28, 2025
pulisher
Mar 27, 2025

Soleno breaks through with FDA nod for Prader-Willi syndrome treatment Vykat XR - Fierce Pharma

Mar 27, 2025
pulisher
Mar 27, 2025

Soleno jumps as analysts say US nod for rare disease drug transforms treatment options - Marketscreener.com

Mar 27, 2025
pulisher
Mar 27, 2025

SLNO Stock Rallies on FDA Approval of Prader-Willi Syndrome Drug - Yahoo Finance

Mar 27, 2025
pulisher
Mar 27, 2025

Acadia Pharmaceuticals principal accounting officer sells $18k in stock By Investing.com - Investing.com Canada

Mar 27, 2025
pulisher
Mar 26, 2025

Acadia Pharmaceuticals CFO sells $54,065 in stock By Investing.com - Investing.com Canada

Mar 26, 2025
pulisher
Mar 26, 2025

Acadia Pharmaceuticals CFO sells $54,065 in stock - Investing.com India

Mar 26, 2025
pulisher
Mar 26, 2025

Acadia Pharmaceuticals principal accounting officer sells $18k in stock - Investing.com

Mar 26, 2025
pulisher
Mar 25, 2025

Is ACADIA Pharmaceuticals Inc. (ACAD) a Promising Biotech Stock According to Wall Street Analysts - Insider Monkey

Mar 25, 2025
pulisher
Mar 25, 2025

Psychosis in Parkinson's and Alzheimer's Disease Market: - openPR

Mar 25, 2025
pulisher
Mar 24, 2025

Parkinson's Disease Psychosis Treatment Market Size in 7MM - openPR

Mar 24, 2025
pulisher
Mar 20, 2025

Acadia Pharmaceuticals Initiates Phase 2 Clinical Trial of ACP-204 for the Treatment of Alzheimer’s Disease Psychosis - Business Wire

Mar 20, 2025
pulisher
Mar 18, 2025

Acadia Pharmaceuticals Announces DAYBUE™ (trofinetide) is Now Available for the Treatment of Rett Syndrome - Business Wire

Mar 18, 2025
pulisher
Mar 17, 2025

Is ACADIA Pharmaceuticals Inc. (ACAD) the Best Nasdaq Stock Under $20 to Buy Now? - Insider Monkey

Mar 17, 2025
pulisher
Mar 17, 2025

ACADIA Pharmaceuticals Earns RS Rating Upgrade - Investor's Business Daily

Mar 17, 2025
pulisher
Mar 16, 2025

Former San Diego Pharma VP pleads guilty to securities fraud for insider trading - MSN

Mar 16, 2025
pulisher
Mar 16, 2025

Ryan Reynolds Announces More to Parkinson’s® Campaign - Business Wire

Mar 16, 2025
pulisher
Mar 14, 2025

Acadia Pharmaceuticals issues new employee stock awards By Investing.com - Investing.com Australia

Mar 14, 2025
pulisher
Mar 14, 2025

Acadia Pharmaceuticals issues new employee stock awards - Investing.com India

Mar 14, 2025
pulisher
Mar 13, 2025

Acadia Sets Stage for Strategic Updates at 3 Major CNS ConferencesKey Dates for Investors - StockTitan

Mar 13, 2025
pulisher
Mar 12, 2025

ACADIA Pharmaceuticals’ SWOT analysis: stock outlook amid pipeline progress By Investing.com - Investing.com South Africa

Mar 12, 2025
pulisher
Mar 12, 2025

ACADIA Pharmaceuticals’ SWOT analysis: stock outlook amid pipeline progress - Investing.com India

Mar 12, 2025
pulisher
Mar 12, 2025

Proficio Capital Partners LLC Invests $272,000 in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) - Defense World

Mar 12, 2025
pulisher
Mar 12, 2025

Parkinson's Disease Therapeutics Market is expected to reach - openPR

Mar 12, 2025
pulisher
Mar 11, 2025

ACADIA Pharmaceuticals Q4 Earnings: EPS Soars to $0.86, Beating Estimates, While Revenue Misses at $259.6 Million - GuruFocus.com

Mar 11, 2025
pulisher
Mar 10, 2025

Calif. Pharma Exec Pleads Guilty To Insider Trading - Law360

Mar 10, 2025
pulisher
Mar 10, 2025

SEC Sues Former Acadia Pharmaceuticals VP Over Insider Trading - Bloomberg Law News

Mar 10, 2025
pulisher
Mar 10, 2025

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Acadia Pharmaceuticals (ACAD) Investors with Losses to Contact Its Attorneys, Firm Investigating ACAD for Possible Securities Law Violations - ACCESS Newswire

Mar 10, 2025
pulisher
Mar 09, 2025

Former Vice President of San Diego-Based Acadia Pharmaceutical Company Admits to Insider Trading - Sierra Sun Times

Mar 09, 2025

Acadia Pharmaceuticals Inc (ACAD) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$20.07
price up icon 0.15%
$69.51
price down icon 4.32%
$32.19
price down icon 1.26%
$25.22
price up icon 2.48%
$101.81
price up icon 3.09%
biotechnology ONC
$229.22
price down icon 0.76%
자본화:     |  볼륨(24시간):